5-碘-2-甲氧基吡啶 | 13472-61-2

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-碘-2-甲氧基吡啶
• 中文别名: 2-甲氧基-5-碘吡啶；6-甲氧基-3-碘吡啶；5-碘-2-甲氧吡啶
• 英文名称: 5-iodo-2-methoxypyridine
• 英文别名: 2-methoxy-5-iodopyridine
• CAS: 13472-61-2
• 化学式: C₆H₆INO
• mdl: MFCD07781180
• 分子量: 235.024
• InChiKey: NTXRNCUPGYOZCN-UHFFFAOYSA-N

物化性质

• 沸点：
  237℃
• 密度：
  1.825
• 闪点：
  97℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-Iodo-2-methoxypyridine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
5-Iodo-2-methoxypyridine
Ingredient name:
CAS number: 13472-61-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H6INO
Molecular weight: 235

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-碘-2-甲氧基吡啶 在 lithium chloro-isopropyl-magnesium chloride 、 甲醇 作用下， 反应 1.25h， 以61%的产率得到2-甲氧基吡啶
  参考文献：
  名称：

  叔丁基亚磺酰胺辅助剂的镁基非对映选择性制备吡啶基1,3-氨基醇

  摘要：

  摘要 通过使用两步法制备1,3-氨基醇，并讨论了非对映选择性的有趣逆转。 通过使用两步法制备1,3-氨基醇，并讨论了非对映选择性的有趣逆转。

  DOI：

  10.1055/s-0034-1378854
• 作为产物：
  描述：

  2-甲氧基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 、 异丙基氯化镁 作用下， 以 四氢呋喃 、 正己烷 、 乙腈 为溶剂， 反应 20.75h， 生成 5-碘-2-甲氧基吡啶
  参考文献：
  名称：

  二丁基（异丙基）镁酸锂（1-）和氯化锂通过卤素-镁交换进行非低温合成功能化的2-甲氧基吡啶

  摘要：

  使用二丁基（异丙基）镁酸锂（1-）和相应的溴或碘类似物制备在3-，5-或6-位官能化的2-甲氧基吡啶和在3-位官能化的2,6-二甲氧基吡啶。非低温条件下的氯化锂。根据在两种镁酸盐之间的选择以及反应介质中氯化锂的存在与否，对程序进行了优化。 吡啶-镁-锂-有机金属试剂

  DOI：

  10.1055/s-0031-1289687
• 作为试剂：
  描述：

  1-氯-1-苯基丙烷 在 乙二醇二甲醚溴化镍 、 5-碘-2-甲氧基吡啶 、 三甲基氯硅烷 、 (4S,4'S)-4,4'-di(heptan-4-yl)-4,4',5,5'-tetrahydro-2,2'-bioxazole 、 锌 作用下， 以 1,4-二氧六环 为溶剂， 反应 18.0h， 以26%的产率得到3,4-diphenyl-hexane
  参考文献：
  名称：

  镍催化不对称还原交叉偶联获得 1,1-二芳基烷烃

  摘要：

  已经开发了（杂）芳基碘化物和苄基氯化物的不对称 Ni 催化还原交叉偶联，以制备对映体富集的 1,1-二芳基烷烃。作为这些研究的一部分，开发了一种新的手性生物恶唑啉配体 4-庚基-BiOX (L1)，以便以合成有用的产率和对映选择性获得产品。该反应耐受多种杂环偶联物，包括吡啶、嘧啶、吲哚和哌啶。

  DOI：

  10.1021/jacs.7b01705

文献信息

• Synthesis of Pyridylsulfonium Salts and Their Application in the Formation of Functionalized Bipyridines
  作者：Vincent K. Duong、Alexandra M. Horan、Eoghan M. McGarrigle

  DOI：10.1021/acs.orglett.0c03048

  日期：2020.11.6

  arylation of pyridylsulfides with good functional group tolerance was developed. To demonstrate synthetic utility, the resulting pyridylsulfonium salts were used in a scalable transition-metal-free coupling protocol, yielding functionalized bipyridines with extensive functional group tolerance. This modular methodology permits selective introduction of functional groups from commercially available pyridyl

  开发了具有良好官能团耐受性的吡啶基硫醚的S选择性芳基化反应。为了证明其合成实用性，将所得吡啶基yl盐用于可扩展的无过渡金属偶联方案中，得到具有广泛官能团耐受性的官能化联吡啶。该模块化方法允许从可商购的吡啶基卤中选择性引入官能团，从而提供对称和不对称的2,2'-和2,3'-联吡啶。该方法的迭代应用使得能够合成具有三种不同吡啶组分的官能化的吡啶。
• Enantioselective Three-Component Fluoroalkylarylation of Unactivated Olefins through Nickel-Catalyzed Cross-Electrophile Coupling
  作者：Hai-Yong Tu、Fang Wang、Liping Huo、Yuanbo Li、Shengqing Zhu、Xian Zhao、Huan Li、Feng-Ling Qing、Lingling Chu

  DOI：10.1021/jacs.0c03708

  日期：2020.5.27

  A nickel-catalyzed, enantioselective, three-component fluoroalkylarylation of unactivated alkenes with aryl halides and perfluoroalkyl iodides has been described. This cross-electrophile coupling protocol utilizes a chiral nickel/BiOx system as well as a pendant chelating group to facilitate the challenging three-component, asymmetric difunctionalization of unactivated alkenes, providing direct access

  镍催化、对映选择性、三组分氟烷基芳基化未活化的烯烃与芳基卤化物和全氟烷基碘化物已被描述。这种交叉亲电偶联方案利用手性镍/BiOx 系统以及悬垂的螯合基团来促进未活化烯烃的具有挑战性的三组分不对称双官能化，从而以高效和出色的对映选择性直接获得有价值的手性 β-氟烷基芳基烷烃. 温和的条件允许广泛的底物范围以及良好的官能团耐受性。
• COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES
  申请人：OxaluRx, Inc.

  公开号：US20210052586A1

  公开（公告）日：2021-02-25

  Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.

  本文披露了用于调节甘醇酸氧化酶的化合物和组合物，用于治疗与草酸盐相关的疾病，如高草酸尿症，其中调节甘醇酸氧化酶预计对需要治疗的患者具有疗效。还提供了在人类或动物主体中调节甘醇酸氧化酶活性的方法。
• [EN] BENZOTHIADIAZINE COMPOUNDS<br/>[FR] COMPOSÉS BENZOTHIADIAZINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098421A1

  公开（公告）日：2017-06-15

  The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代苯并噻二嗪衍生物。具体而言，本发明涉及式(I)化合物：其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病，如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
• [EN] ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS D'ÉTHYNE, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012032014A1

  公开（公告）日：2012-03-15

  invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及公式I的新化合物，涉及它们作为药物的用途，涉及它们的治疗用途的方法，以及含有它们的药物组合物。

表征谱图